In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk melanoma, while the FDA granted expedited review and an August 5, 2026 ...

Combined with the administration’s erratic regulation and policymaking, it threatens to undo the salutary ecosystem that made ...

Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

The Food and Drug Administration has refused to review an application from the biotech company Moderna to approve its mRNA-based flu vaccine. The agency’s decision, which Moderna announced in a press ...

By Mariam Sunny and Michael Erman Feb 18 (Reuters) - Moderna said on Wednesday the U.S. Food and Drug Administration changed ...

Add Yahoo as a preferred source to see more of our stories on Google. The FDA's decision this week to reverse course and review Moderna's seasonal flu vaccine application followed a meeting in which ...

The U.S. Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday.About two weeks ago, the FDA sent Moderna a ...

The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for approval of its new flu vaccine, which is its first using mRNA technology ...

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday.The news is the ...

Add Yahoo as a preferred source to see more of our stories on Google. In December 2025, Moderna submitted an application to the FDA to approve the first mRNA-based flu vaccine. Catherine Falls ...

WASHINGTON (AP) — The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday ...